S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.33 (-0.95%)
BABA   85.62 (-0.34%)
AMD   97.53 (+1.64%)
T   14.83 (-1.26%)
F   12.32 (-0.88%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   110.93 (+0.91%)
DIS   79.29 (-0.95%)
AMC   7.77 (-1.77%)
PFE   31.96 (-1.36%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.33 (-0.95%)
BABA   85.62 (-0.34%)
AMD   97.53 (+1.64%)
T   14.83 (-1.26%)
F   12.32 (-0.88%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   110.93 (+0.91%)
DIS   79.29 (-0.95%)
AMC   7.77 (-1.77%)
PFE   31.96 (-1.36%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.33 (-0.95%)
BABA   85.62 (-0.34%)
AMD   97.53 (+1.64%)
T   14.83 (-1.26%)
F   12.32 (-0.88%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   110.93 (+0.91%)
DIS   79.29 (-0.95%)
AMC   7.77 (-1.77%)
PFE   31.96 (-1.36%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.33 (-0.95%)
BABA   85.62 (-0.34%)
AMD   97.53 (+1.64%)
T   14.83 (-1.26%)
F   12.32 (-0.88%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   110.93 (+0.91%)
DIS   79.29 (-0.95%)
AMC   7.77 (-1.77%)
PFE   31.96 (-1.36%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
NASDAQ:NURO

NeuroMetrix (NURO) Stock Forecast, Price & News

$0.60
-0.02 (-3.31%)
(As of 01:12 PM ET)
Compare
Today's Range
$0.60
$0.63
50-Day Range
$0.64
$0.98
52-Week Range
$0.60
$3.45
Volume
35,161 shs
Average Volume
65,720 shs
Market Capitalization
$5.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NURO stock logo

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NURO Price History

NURO Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
NeuroMetrix Reports Q2 2023 Business Highlights
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
NeuroMetrix Reports Q1 2023 Financial Results
Why NeuroMetrix (NURO) Stock Is Soaring Today
See More Headlines
Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Company Calendar

Last Earnings
7/27/2023
Today
9/27/2023
Next Earnings (Estimated)
10/19/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NURO
Employees
27
Year Founded
1996

Profitability

Net Income
$-4,420,000.00
Pretax Margin
-75.17%

Debt

Sales & Book Value

Annual Sales
$7.20 million
Book Value
$3.01 per share

Miscellaneous

Free Float
7,941,000
Market Cap
$5.49 million
Optionable
Not Optionable
Beta
2.28

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Shai N. Gozani M.D. (Age 58)
    Ph.D., Founder, Chairman, CEO, Pres & Sec.
    Comp: $437.82k
  • Mr. Thomas T. HigginsMr. Thomas T. Higgins (Age 71)
    Sr. VP, CFO & Treasurer
    Comp: $342.87k
  • Dr. Xuan Kong Ph.D.
    Chief Data Scientist
  • Ms. Susan M. Bell R.N.
    Sr. VP of Population Health & Value Based Care













NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2023?

NeuroMetrix's stock was trading at $1.49 on January 1st, 2023. Since then, NURO shares have decreased by 57.1% and is now trading at $0.6390.
View the best growth stocks for 2023 here
.

When is NeuroMetrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 19th 2023.
View our NURO earnings forecast
.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings results on Thursday, July, 27th. The medical device company reported ($0.19) EPS for the quarter. The medical device company had revenue of $1.66 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 24.38% and a negative net margin of 75.17%.

When did NeuroMetrix's stock split?

NeuroMetrix's stock reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

What is NeuroMetrix's stock symbol?

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroMetrix's stock price today?

One share of NURO stock can currently be purchased for approximately $0.64.

How much money does NeuroMetrix make?

NeuroMetrix (NASDAQ:NURO) has a market capitalization of $5.49 million and generates $7.20 million in revenue each year. The medical device company earns $-4,420,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How can I contact NeuroMetrix?

NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.

This page (NASDAQ:NURO) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -